Andrea Lobo,  —

Levels of fractional exhaled nitric oxide (FeNO) — a measure of how much nitric oxide a person exhales — may be used as a diagnostic tool for severe disease in people with idiopathic pulmonary arterial hypertension (iPAH), a study has found. Specifically, patients with FeNO levels lower than 23…

Findings of a new study into pericytes — cells with multiple functions including immune cell regulation — suggest that targeting a protein known as HIF-2alpha, which is involved in the response to low oxygen conditions, or hypoxia, may be a potential therapeutic approach for pulmonary arterial hypertension (PAH). The…

The U.S. Food and Drug Administration (FDA) has supported Inhibikase Therapeutics’ Phase 2/3 trial of its experimental formulation of imatinib, called IkT-001Pro, for pulmonary arterial hypertension (PAH), the company reports. In a meeting, the FDA asked the company to complete a preclinical study in cells to compare…

Chiesi Group has reached an agreement with Gossamer Bio to develop and market seralutinib for certain types of pulmonary hypertension (PH). The agreement seeks to support the therapy’s ongoing testing in pulmonary arterial hypertension (PAH) and to accelerate its development for pulmonary hypertension associated with…

A diet poor in two amino acids called glutamine and serine may improve the health of pulmonary blood vessels and reduce the progression of pulmonary hypertension (PH), according to a recent study. Specifically, researchers found that these amino acids are used by cells in blood vessels to produce other…

Low levels of PM20D1, a molecule involved in metabolizing lipids, were identified as a risk factor for mortality in people with pulmonary arterial hypertension (PAH), a study reports. As a result, PM20D1, or peptidase M20 domain containing 1, may be a biomarker of disease prognosis, according to scientists. Lipid…

Two genes were identified as potential drivers of pulmonary arterial hypertension (PAH) in people with HIV-1 infection in a bioinformatics study, offering new perspectives to uncover the underlying molecular mechanisms that link HIV infection and PAH. The genes ISG15 and IFI27 are established hub genes involved in the type…

Low levels of circular RNA Alstrom syndrome protein 1, or circALMS1, may be associated with poor outcomes with pulmonary hypertension (PH), a study suggests. This may be because low circALMS1 levels promote higher numbers and the migration of pulmonary microvascular endothelial cells (PMECs), and reduce the cells’ death. PMECs…

Most people with pulmonary arterial hypertension (PAH) due to connective tissue disease (CTD) who are using Opsumit (macitenan) do so as part of a combination therapy, according to real-world evidence from two U.S. drug registry studies. Its safety and effectiveness, in terms of clinical outcomes, for these patients…

Having pulmonary hypertension (PH) worsens the likelihood of potentially life-threatening cardiac and respiratory complications in people with human immunodeficiency virus (HIV) infection, a U.S. database study reported. Its findings “can inform clinical practice and help healthcare providers make more informed decisions regarding the screening, diagnosis, and management of PH…

Blood levels of microRNA — small RNA molecules that regulate protein production — are decreased in people with pulmonary embolism (PE) compared with healthy people. PE is the cause of chronic thromboembolic pulmonary hypertension (CTEPH). However, higher blood levels of miR-let7a were found in people with acute PE who…

Despite having more favorable clinical measures, such as blood flow, men with pulmonary arterial hypertension (PAH) have a higher mortality risk than women with the disease, according to a recent study. This is known as the “sex paradox” and may occur because men may develop PAH only if higher…